Clinical Fellow – Stereotactic Ablative Body Radiotherapy | The Christie NHS Foundation Trust

Dyddiad hysbysebu:	26 Medi 2025
Cyflog:	Heb ei nodi
Gwybodaeth ychwanegol am y cyflog:	£52,656 - £73,992 Per Annum
Oriau:	Llawn Amser
Dyddiad cau:	26 Hydref 2025
Lleoliad:	Manchester, M20 4BX
Cwmni:	The Christie NHS Foundation Trust
Math o swydd:	Cytundeb
Cyfeirnod swydd:	7510584/413-MD-C2025-24622-OO

Crynodeb

Applications are welcomed for a 12 month SABR clinical fellow post commencing December 2025 in Clinical Oncology, based at The Christie NHS FT, Manchester, UK Europe’s largest single site cancer hospital.

This post is for 40 hours per week as a Clinical Fellow for the development and implementation of Stereotactic Ablative Body Radiotherapy (SABR) within the organisationfor a fixed term period of 12 months with the option to extend for up to a further 12 months. The post holder will be employed by The Christie NHS Foundation Trust and will be based at The Christie. The successful applicant would be expected to work alongside consultants and trainees in out-patient clinics, supervising Technical Radiotherapy delivery and performing on-treatment reviews and follow-up assessments.

The post holder will be involved in all aspects of the management of patients with HBT and oligometastatic disease. These include (but are not limited to) the screening of referrals, active participation in MDT, assessment of patients, consent, review of patients on pre-treatment, treatment, planning of SABR, review and approval of SABR plans, technical radiotherapy development and post treatment and ePROMS. All of this will be done under the clinical supervision of the designated SABR team consultant

They will be expected to teach junior medical staff, medical students and nurses on occasion.

They will be expected to take part in audit and research.

There is no on call responsibility with this post.

The Christie is one of Europe’s leading cancer centres, treating over 60,000 patients a year. We are based in Manchester and serve a population of 3.2 million across Greater Manchester & Cheshire, but as a national specialist around 15% patients are referred to us from other parts of the country.

We provide radiotherapy through one of the largest radiotherapy departments in the world; chemotherapy on site and through 14 other hospitals; highly specialist surgery for complex and rare cancer; and a wide range of support and diagnostic services. We are also an international leader in research, with world first breakthroughs for over 100 years.

We run one of the largest early clinical trial units in Europe with over 300 trials every year. Cancer research in Manchester, most of which is undertaken on the Christie site, has been officially ranked the best in the UK.

The successful applicant would be expected to work alongside consultants and trainees in outpatient clinics across a number of disease groups, supervising Technical Radiotherapy delivery and performing on-treatment reviews and follow-up assessments.
The role will be responsible for:
• The appointee will be a Fellow in the department of Clinical Oncology
• The employing authority is The Christie NHS Foundation Trust
• S/he will be managerially accountable to the Clinical Director of the Directorate of Clinical
Oncology
• S/he will be professionally responsible to the consultants in whose clinics s/he will be
supporting.
• The post-holder will be assigned a clinical supervisor (Consultant Clinical Oncologist). They
will work alongside their supervisor in at least one clinic.
• Will develop expertise in the development, management and treatment of HPB and
oligometastatic tumour sites with SABR

The Clinical Oncology establishment currently consists of 59 Consultants who run the clinical service and research practice. There is also a team of 24 SpRs plus Academic and Clinical Fellows.

The appointee will be based at The Christie and will provide senior input to all aspects of the management of patients with HBT and oligometastatic disease. These include (but are not limited to) the screening of referrals, active participation in MDT, assessment of patients, consent, review of patients on pre-treatment, treatment, planning of SABR, review and approval of SABR plans, technical radiotherapy development and post treatment and ePROMS.

All of this will be done under the clinical supervision of the designated SABR team consultant.




This advert closes on Friday 10 Oct 2025

Aelod balch o'r cynllun cyflogwyr Hyderus o ran Anabledd

Gwybodaeth am Hyderus o ran Anabledd

Yn gyffredinol, bydd cyflogwr Hyderus o ran Anabledd yn cynnig cyfweliad i unrhyw ymgeisydd sy'n datgan eu bod yn anabl ac yn bodloni'r meini prawf lleiaf ar gyfer y swydd fel y diffinnir gan y cyflogwr. Mae'n bwysig nodi, mewn rhai sefyllfaoedd recriwtio fel nifer fawr o ymgeiswyr, cyfnod tymhorol ac amseroedd prysur iawn, efallai y bydd y cyflogwr am gyfyngu ar y niferoedd cyffredinol o gyfweliadau a gynigir i bobl anabl a phobl nad ydynt yn anabl. Am fwy o fanylion ewch i Hyderus o ran Anabledd.